FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310568087> ?p ?o ?g. }

• W4310568087 abstract "Objective Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This systematic review summarized evidence on the effectiveness and safety of palivizumab when used in approved populations. Study Design A systematic review of Phase III trials and observational studies was conducted according to the population, intervention, comparator, outcome, timing, setting (PICOTS) approach (PROSPERO, CRD42021281380). Target populations consisted of infants with a history of premature birth (≤35-week gestational age) and children aged <2 years with bronchopulmonary dysplasia (BPD) or with hemodynamically significant congenital heart disease (hs-CHD). Outcomes of interest included RSV-related hospitalization, admission to intensive care unit (ICU), requirement for mechanical ventilation, treatment-related adverse events (AEs), and RSV-related deaths. Information sources were literature search (Ovid MEDLINE and Embase), pragmatic searches, and snowballing (covering the period up to 07 September 2021). Results A total of 60 sources were included (5 Phase III trials and 55 observational studies). RSV-related hospitalization rates following palivizumab prophylaxis in Phase III trials were 1.8% in premature infants and 7.9% in children with BPD, which were significantly lower than rates in placebo arms. In the real-world setting, similar hospitalization rates were found (0.7–4.0% in premature infants [16 studies] and 0–5.5% in patients with BPD [10 studies]) with ICU admission reported in 0 to 33.3% of patients hospitalized for RSV. In Phase III trials, RSV-related mortality rates were 0.2 and 0.3%, while AEs occurred in 11% of premature and/or BPD patients and 7.2% of hs-CHD patients, consisting mainly of injection site reaction, fever, and diarrhea. Similar results were found in observational studies. Conclusion This systematic review supports the effectiveness and safety of palivizumab in the indicated populations. Key Points" @default.
• W4310568087 created "2022-12-12" @default.
• W4310568087 creator A5001059960 @default.
• W4310568087 creator A5011768314 @default.
• W4310568087 creator A5017739734 @default.
• W4310568087 creator A5027419324 @default.
• W4310568087 creator A5030251585 @default.
• W4310568087 creator A5041388207 @default.
• W4310568087 creator A5054302211 @default.
• W4310568087 creator A5084063286 @default.
• W4310568087 creator A5086152092 @default.
• W4310568087 date "2022-11-30" @default.
• W4310568087 modified "2023-10-03" @default.
• W4310568087 title "Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review" @default.
• W4310568087 cites W149750147 @default.
• W4310568087 cites W1589200039 @default.
• W4310568087 cites W1965403603 @default.
• W4310568087 cites W1982129670 @default.
• W4310568087 cites W1982858040 @default.
• W4310568087 cites W1988087621 @default.
• W4310568087 cites W2014939976 @default.
• W4310568087 cites W2014975115 @default.
• W4310568087 cites W2029503764 @default.
• W4310568087 cites W2030168619 @default.
• W4310568087 cites W2031859673 @default.
• W4310568087 cites W2038255976 @default.
• W4310568087 cites W2046093522 @default.
• W4310568087 cites W2052432399 @default.
• W4310568087 cites W2063305435 @default.
• W4310568087 cites W2067738939 @default.
• W4310568087 cites W2075907998 @default.
• W4310568087 cites W2081597687 @default.
• W4310568087 cites W2086373045 @default.
• W4310568087 cites W2120949068 @default.
• W4310568087 cites W2125492557 @default.
• W4310568087 cites W2142073032 @default.
• W4310568087 cites W2151440859 @default.
• W4310568087 cites W2223258418 @default.
• W4310568087 cites W2320421839 @default.
• W4310568087 cites W2468188527 @default.
• W4310568087 cites W2528034031 @default.
• W4310568087 cites W2528127819 @default.
• W4310568087 cites W2531269403 @default.
• W4310568087 cites W2559877112 @default.
• W4310568087 cites W2560160716 @default.
• W4310568087 cites W2573237218 @default.
• W4310568087 cites W2576761417 @default.
• W4310568087 cites W2586644068 @default.
• W4310568087 cites W2763496938 @default.
• W4310568087 cites W2765706322 @default.
• W4310568087 cites W2766648230 @default.
• W4310568087 cites W2793796430 @default.
• W4310568087 cites W2793897010 @default.
• W4310568087 cites W2808781849 @default.
• W4310568087 cites W2907551323 @default.
• W4310568087 cites W2916194089 @default.
• W4310568087 cites W2924268563 @default.
• W4310568087 cites W2947993281 @default.
• W4310568087 cites W2955967732 @default.
• W4310568087 cites W2970563684 @default.
• W4310568087 cites W3004553904 @default.
• W4310568087 cites W3015800380 @default.
• W4310568087 cites W3107990723 @default.
• W4310568087 cites W3125991256 @default.
• W4310568087 cites W3127197120 @default.
• W4310568087 cites W4254903140 @default.
• W4310568087 cites W4292315834 @default.
• W4310568087 doi "https://doi.org/10.1055/a-1990-2633" @default.
• W4310568087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36452969" @default.
• W4310568087 hasPublicationYear "2022" @default.
• W4310568087 type Work @default.
• W4310568087 citedByCount "4" @default.
• W4310568087 countsByYear W43105680872023 @default.
• W4310568087 crossrefType "journal-article" @default.
• W4310568087 hasAuthorship W4310568087A5001059960 @default.
• W4310568087 hasAuthorship W4310568087A5011768314 @default.
• W4310568087 hasAuthorship W4310568087A5017739734 @default.
• W4310568087 hasAuthorship W4310568087A5027419324 @default.
• W4310568087 hasAuthorship W4310568087A5030251585 @default.
• W4310568087 hasAuthorship W4310568087A5041388207 @default.
• W4310568087 hasAuthorship W4310568087A5054302211 @default.
• W4310568087 hasAuthorship W4310568087A5084063286 @default.
• W4310568087 hasAuthorship W4310568087A5086152092 @default.
• W4310568087 hasBestOaLocation W43105680871 @default.
• W4310568087 hasConcept C126322002 @default.
• W4310568087 hasConcept C142724271 @default.
• W4310568087 hasConcept C177713679 @default.
• W4310568087 hasConcept C187212893 @default.
• W4310568087 hasConcept C204787440 @default.
• W4310568087 hasConcept C23131810 @default.
• W4310568087 hasConcept C27081682 @default.
• W4310568087 hasConcept C2776012195 @default.
• W4310568087 hasConcept C2776399701 @default.
• W4310568087 hasConcept C2777091541 @default.
• W4310568087 hasConcept C2778376644 @default.
• W4310568087 hasConcept C2778644256 @default.
• W4310568087 hasConcept C2778721537 @default.
• W4310568087 hasConcept C2778821649 @default.
• W4310568087 hasConcept C2779234561 @default.
• W4310568087 hasConcept C2908647359 @default.

• next